全文获取类型
收费全文 | 302393篇 |
免费 | 12903篇 |
国内免费 | 6388篇 |
专业分类
耳鼻咽喉 | 2411篇 |
儿科学 | 8605篇 |
妇产科学 | 5996篇 |
基础医学 | 29902篇 |
口腔科学 | 4306篇 |
临床医学 | 28122篇 |
内科学 | 50332篇 |
皮肤病学 | 2244篇 |
神经病学 | 22822篇 |
特种医学 | 13128篇 |
外国民族医学 | 40篇 |
外科学 | 42370篇 |
综合类 | 21435篇 |
现状与发展 | 20篇 |
一般理论 | 22篇 |
预防医学 | 27334篇 |
眼科学 | 6173篇 |
药学 | 22857篇 |
113篇 | |
中国医学 | 7103篇 |
肿瘤学 | 26349篇 |
出版年
2024年 | 114篇 |
2023年 | 1604篇 |
2022年 | 2561篇 |
2021年 | 5049篇 |
2020年 | 4129篇 |
2019年 | 3853篇 |
2018年 | 25718篇 |
2017年 | 20945篇 |
2016年 | 22669篇 |
2015年 | 6254篇 |
2014年 | 7699篇 |
2013年 | 7889篇 |
2012年 | 17300篇 |
2011年 | 31883篇 |
2010年 | 26163篇 |
2009年 | 17626篇 |
2008年 | 27256篇 |
2007年 | 29354篇 |
2006年 | 8000篇 |
2005年 | 8960篇 |
2004年 | 8286篇 |
2003年 | 8787篇 |
2002年 | 6175篇 |
2001年 | 3373篇 |
2000年 | 3264篇 |
1999年 | 2802篇 |
1998年 | 1472篇 |
1997年 | 1370篇 |
1996年 | 1056篇 |
1995年 | 1064篇 |
1994年 | 984篇 |
1993年 | 573篇 |
1992年 | 960篇 |
1991年 | 924篇 |
1990年 | 819篇 |
1989年 | 659篇 |
1988年 | 593篇 |
1987年 | 510篇 |
1986年 | 397篇 |
1985年 | 325篇 |
1984年 | 212篇 |
1983年 | 207篇 |
1982年 | 126篇 |
1981年 | 100篇 |
1980年 | 112篇 |
1979年 | 157篇 |
1978年 | 129篇 |
1977年 | 92篇 |
1974年 | 123篇 |
1972年 | 95篇 |
排序方式: 共有10000条查询结果,搜索用时 19 毫秒
21.
Tianshu Liu Yuxian Bai Xiaoyan Lin Wei Li Jufeng Wang Xiaochun Zhang Hongming Pan Chunmei Bai Li Bai Ying Cheng Jingdong Zhang Haijun Zhong Yi Ba Wenwei Hu Ruihua Xu Weijian Guo Shukui Qin Nong Yang Jianwei Lu Kohei Shitara Ming Lei Mingshun Li Nicole Bao Tian Chen Lin Shen 《International journal of cancer. Journal international du cancer》2023,152(4):749-760
First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC. 相似文献
22.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
23.
24.
25.
Xiaoliang Bai Yong Lian Changqing Hu Shuai Yang Bo Pei Mingyan Yao Xiaojuan Zhu Lin Shang Zhihong Li 《Journal of applied toxicology : JAT》2022,42(7):1137-1145
Cyanidin-3-glucoside (C3G) is a well-known natural anthocyanin with antioxidant and anti-inflammatory properties. In this study, we explored the role and action mechanism of C3G in high glucose (HG)-induced damage of human nucleus pulposus cells (HNPCs). Cell viability was assessed by CCK-8 assay. TUNEL assay was performed for detecting apoptotic rate. Western blot was performed to determine the expression levels of cl-caspase-3, caspase-3, Bax, Bim, collagen II, aggrecan, MMP-3, MMP-13, and ADAMTS5. Reactive oxygen species (ROS) generation was analyzed using DCFH-DA staining. The Nrf2 was knocked down or overexpressed in HNPCs through transfection with si-Nrf2 or pcDNA3.0-Nrf2. C3G treatment (12.5, 25, and 50 μM) improved cell viability of HNPCs under HG condition. HG-induced cell apoptosis of HNPCs was attenuated by C3G with decreased apoptotic rate and relative levels of cl-caspase-3/caspase-3, Bax, and Bim. C3G treatment caused significant increase in expression levels of collagen II and aggrecan and decrease in the relative levels of MMP-3, MMP-13, and ADAMTS5. After treatment with C3G, ROS generation in HNPCs was markedly reduced. Treatment with N-acetylcysteine (NAC) reversed HG-induced cell apoptosis and extracellular matrix (ECM) degradation. C3G treatment induced the expression of Nrf2 and HO-1 in HG-induced HNPCs. Moreover, knockdown of Nrf2 reversed the inhibitory effect of C3G on ROS production. Summarily, C3G exerted a protective effect on ROS-mediated cellular damage in HNPCs under HG condition, which was attributed to the induction of the Nrf2/HO-1 signaling pathway. 相似文献
26.
27.
目的 分析双水平气道正压双水平气道正压通气(bi-level positive airway pressure,BiPAP)对阻塞性睡眠呼吸暂停低通气综合征(obstructive sleep apnea hypopnea syndrome,OSAHS)患者血管内皮功能及预后的影响。
方法 将100例OSAHS患者纳入研究,随机分为观察及对照组,各50例。观察组行BiPAP
,对照组行常规治疗,比较两组多导睡眠监测(polysomnography,PSG)检查指标(低通气指数、呼吸暂停指数、呼吸暂停及低通气时间、90%以下血氧饱和度次数、90%以下血氧饱和度时间)、心肺功能[脑钠肽(brainnatriureticpeptide,BNP)、右心室Tei指数、左心室Tei指数、一秒用力呼气容积占用力肺活量的百分比(forced expiratory volume in one second/forced vital capacity,FEV1/FVC)、一秒用力呼气容积占预计值的百分比(FEV1占预计值%)]、血管内皮功能[内皮素1(endothelin-1,ET-1)、一氧化氮(nitric oxide,NO)、凝血酶Ⅲ(antithrombin Ⅲ,AT-Ⅲ)]及生活质量。
结果 观察组低通气指数、呼吸暂停指数、呼吸暂停及低通气时间、90%以下血氧饱和度次数及时间指标均显著低于对照组(P<0.05)。观察组治疗后BNP以及Tei指数显著低于治疗前及对照组治疗后,FEV1/FVC、FEV1占预计值%显著高于治疗前及对照组治疗后(P<0.05)。观察组治疗后ET-1、AT-Ⅲ低于治疗前及对照组治疗后,NO高于治疗前及对照组治疗后(P<0.05)。观察组治疗后生活质量各项目评分高于对照组(P<0.05)。
结论 BiPAP治疗能够改善OSAHS患者的预后情况及血管内皮功能,效果确切。 相似文献
28.
目的 调查石河子地区近十年结肠镜下成人结直肠癌(colorectal cancer,CRC)、结直肠腺瘤和进展期腺瘤检出率的变化趋势。方法 2010年1月1日—2019年12月31日期间,就诊于石河子大学医学院第一附属医院完成结肠镜检查的病例纳入调查,通过查阅电子病历系统收集病历资料,具体信息包括患者年龄、性别及结直肠腺瘤或CRC的部位、数量、大小和病理类型等。主要观察结直肠腺瘤、结直肠进展期腺瘤和CRC的检出率,包括10年总体检出率以及前五年(2010—2014年)总体检出率和后五年(2015—2019年)总体检出率。结果 共纳入50 645例,经排除标准排除14 931例,最终共35 714例纳入数据分析。结直肠腺瘤、结直肠进展期腺瘤和CRC的10年总体检出率分别为17.65%(6 302/35 714)、4.45%(1 589/35 714)和3.71%(1 324/35 714)。结直肠腺瘤后五年总体检出率[20.33%(4 565/22 457)]高于前五年[13.10%(1 737/13 257)];结直肠进展期腺瘤后五年总体检出率[4.69%(1 053/22 457)]高于前五年[4.04%(536/13 257)];CRC后五年总体检出率[3.30%(741/22 457)]低于前五年[4.40%(583/13 257)]。结论 石河子地区2015—2019年结直肠腺瘤检出率较2010—2014年有较大幅度升高,结直肠进展期腺瘤检出率较2010—2014年有小幅升高,而CRC检出率较2010—2014年有小幅下降,由此推测结肠镜检查发现并切除结直肠腺瘤对降低CRC发病率可能具有重要作用。 相似文献
29.
30.